323 related articles for article (PubMed ID: 9516599)
1. Taxanes in adjuvant and neoadjuvant therapies for breast cancer.
O'Leary J; Volm M; Wasserheit C; Muggia F
Oncology (Williston Park); 1998 Jan; 12(1 Suppl 1):23-7. PubMed ID: 9516599
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
3. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
Sparano JA
Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
[TBL] [Abstract][Full Text] [Related]
4. Taxanes in the treatment of early breast cancer.
Ring AE; Ellis PA
Cancer Treat Rev; 2005 Dec; 31(8):618-27. PubMed ID: 16266787
[TBL] [Abstract][Full Text] [Related]
5. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
[TBL] [Abstract][Full Text] [Related]
6. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
7. Integration of docetaxel into adjuvant breast cancer treatment regimens.
Hortobagyi GN
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):27-33. PubMed ID: 12108895
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
9. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Crown J
Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
[TBL] [Abstract][Full Text] [Related]
10. Drug treatments for adjuvant chemotherapy in breast cancer: recent trials and future directions.
Dang CT
Expert Rev Anticancer Ther; 2006 Mar; 6(3):427-36. PubMed ID: 16503859
[TBL] [Abstract][Full Text] [Related]
11. The current status of docetaxel in solid tumors. An M. D. Anderson Cancer Center Review.
Hong WK
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):9-15. PubMed ID: 12108903
[TBL] [Abstract][Full Text] [Related]
12. Taxanes in the adjuvant treatment of breast cancer: why not yet?
Piccart MJ; Lohrisch C; Duchateau L; Buyse M
J Natl Cancer Inst Monogr; 2001; (30):88-95. PubMed ID: 11773299
[TBL] [Abstract][Full Text] [Related]
13. Taxanes in the treatment of breast cancer: a prodigy comes of age.
Miller KD; Sledge GW
Cancer Invest; 1999; 17(2):121-36. PubMed ID: 10071597
[TBL] [Abstract][Full Text] [Related]
14. Future perspectives of docetaxel (Taxotere) in front-line therapy.
Piccart MJ; Di Leo A
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel as neoadjuvant chemotherapy in patients with stage III breast cancer.
Gradishar WJ
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):15-8. PubMed ID: 9364536
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
19. The international experience with docetaxel in the treatment of breast cancer.
Ravdin PM
Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):38-42. PubMed ID: 9110341
[TBL] [Abstract][Full Text] [Related]
20. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II, multicenter study.
Estévez LG; Cuevas JM; Antón A; Florián J; López-Vega JM; Velasco A; Lobo F; Herrero A; Fortes J
Clin Cancer Res; 2003 Feb; 9(2):686-92. PubMed ID: 12576436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]